Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial

Journal:
The Lancet Diabetes & Endocrinology
Published:
DOI:
10.1016/s2213-8587(25)00164-0
Affiliations:
7
Authors:
8
Go to article
Institutions Authors Share
Novo Nordisk, Denmark
2.000000
 0.25
Faculty of Medicine Siriraj Hospital, MU, Thailand
1.000000
 0.13
Hallym University Sacred Heart Hospital, HUMC, South Korea
1.000000
 0.13
Konyang University Hospital, South Korea
1.000000
 0.13
Chiang Mai University (CMU), Thailand
1.000000
 0.13
Seoul National University Bundang Hospital (SNUBH), South Korea
1.000000
 0.13
Novo Nordisk China, China
1.000000
 0.13
Interested in Nutrition and Dietetics?